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ess under CC BY-NC-Abstract Kidney-targeted drug delivery systems represent a promising technology to improve drug efﬁcacy
and safety in the treatment of renal diseases. In this review, we summarize the strategies that have been
employed to develop kidney-targeted drug delivery systems. We also describe how macromolecular carriers
and prodrugs play crucial roles in targeting drugs to particular target cells in the kidney. New technologies
render it possible to create renal targeting conjugates and other delivery systems including nanoparticles and
liposomes present promising strategies to achieve the goal of targeting drugs to the kidney.
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P. Zhou et al.381. Introduction
The kidney is a key organ serving several essential functions. It is
responsible for the formation of urine and performs a homeostatic
function in maintaining acid–base balance and regulating electro-
lytes and water to maintain blood pressure. Any disorder in renal
physiological function can lead to serious problems such as
infections of the urinary tract, inﬂammation and hypertension.
Renal disease and systemic disease caused by renal disease occur
throughout the world and are generally difﬁcult to treat.
In the past 10 years, nephropathy has received increasing
attention in developing countries. According to a cross-sectional
survey of 47,204 people, it was found that the overall prevalence
of chronic kidney disease was 10.8%, indicating there could be as
many as 119.5 million people in China with renal disease1. These
patients often incur a considerable ﬁnancial burden since renal
disease can require long-term medication and in some cases
expensive dialysis (¥50,000 per year) or even kidney transplanta-
tion (¥100,000) to prolong life.
Treatment of nephrotic syndrome with drugs such as hormones,
antibiotics and antihypertensive agents often requires high drug
concentrations in the kidney. Unfortunately, such high concentra-
tions are often associated with adverse effects particularly for
drugs such as non-steroidal anti-inﬂammatory drugs (NSAIDs). In
addition, high renal drug concentrations may not translate into
high concentrations in the target cell and, in pathological condi-
tions such as abnormal glomerular ﬁltration, tubular secretion or
proteinuria, the distribution of drugs to the kidney may be affected.
Therefore, kidney-targeted drug delivery is of great signiﬁcance to
overcome these problems and improve the therapeutic index of
drugs used in treating renal disease.2. Strategies
To achieve the goal of kidney-targeted drug delivery, prodrugs2 and
macromolecular carriers3 have been the most common strategies
employed (Fig. 1). Among the macromolecular carriers, proteins,
peptides, antibodies and viruses have been utilized. Prodrugs
capable of selectively targeting the kidney generally release the
active drug through the action of renal enzymes.
Glomerular mesangial cells and proximal tubular cells play an
important role in the etiology of many renal diseases. However,
reports of strategies to target glomerular mesangial cells are very few
and delivery systems are mostly targeted to proximal tubular cells. In
this review, we mainly discuss the targeting of proximal tubular cells.Figure 1 The strategies of kidnProximal tubular epithelial cells are involved in many aspects of
tubular interstitial damage which can contribute to the decline of
renal function. They also promote the formation and development
of interstitial inﬂammation and ﬁbrosis by means of chemotaxis,
antigen-presenting and the action of autocrine and paracrine
cytokines. Proximal tubular cells induced by pathological factors
excessively produce and activate complement (C3) which is an
essential part of the immune response to injury. Blocking this
process can protect renal function and reduce ongoing renal
disease4. Therefore, drug delivery to the proximal tubules can
improve the treatment of kidney disease and reduce adverse effects
on other organs and tissues.
Targeting anti-inﬂammatory and anti-ﬁbrotic drugs to proximal
tubular cells may prevent systemic infection and renal tubular
inﬂammation. In addition, kidney-targeted drug delivery is of great
signiﬁcance in shock, kidney transplantation, ureteral obstruction,
diabetes, proteinuria, and in some diseases involving changes in
renal tubular function such as Fanconi and Bartter0s syndrome.
Targeting proximal tubular cells may provide new ways to treat
renal disease whilst reducing drug toxicity5–9.2.1. Macromolecular carriers
Macromolecular carriers are very useful for targeting drugs to the
kidney, in particular low molecular weight glomerular proteins
(LMWP) which can selectively accumulate in the kidneys. They
are generally small molecular weight (MWo30,000 Da), biologically
active proteins in the circulatory system which include enzymes (such
as lysozyme), immune proteins (such as light chain immunoglobulin)
and peptide hormones (such as insulin). In general, the molecular
weight of the macromolecular carrier is larger than that of the drug
and the kinetics of the protein carrier overrule the intrinsic kinetics of
the drug. LMWP can be ﬁltered at the glomerulus and reabsorbed in
the renal tubules (Fig. 2). Of particular importance is that LMWP are
non-immunogenic and contain functional groups to which drugs can
be linked. Ideally, a drug-macromolecular carrier conjugate is rapidly
removed from the circulation and undergoes drug release and
activation in lysosomes. Normally, distribution of drug released in
the kidney is relatively slow allowing the concentration of drug in the
circulatory system to remain below the level associated with extra-
renal effects10–12.
LMWP can be conjugated to drugs in a variety of ways including
through the formation of peptide, ester, amide and disulﬁde bonds.
The drug can then be released from the conjugate by enzymatic or
chemical hydrolysis. The synthesis of a particular drug–LMWPey-targeted drug delivery systems.
Figure 2 The uptake route of kidney-targeted delivery of drug–carrier conjugates. 1: The drug–carrier conjugates enter rapidly into the renal
tubule in the way of glomerular ﬁltration; 2: the drug–carrier conjugates are reabsorbed by the renal tubule; 3: the drug–carrier conjugates enter
into renal proximal tubular cells; 4: the drugs release and activation in lysosomes.
Kidney–targeted drug delivery 39conjugate requires careful design and a high degree of skill partly
because LMWP have many active groups and are very vulnerable to
self-aggregation. In fact it is often necessary to introduce protecting
groups and use carefully controlled reaction conditions to avoid
LMWP degeneration.2.1.1. Lysozyme
The most studied LMWP is lysozyme, a low molecular weight
endogenous protein with a molecular weight of 14 kDa. Lysozyme
has a number of advantages as a macromolecular carrier including
speciﬁc renal uptake, biodegradability and ease of conjugation
with drugs. One of the most extensively studied kidney-targeted
conjugates is with naproxen13–15 where the drug is linked to
lysozyme by a peptide bond. The naproxen–lysozyme conjugate is
converted into an active metabolite, naproxen–lysine, which can
inhibit cyclooxygenase to the same extent as naproxen itself. After
its uptake by renal proximal tubular cells, naproxen is gradually
released and produces renal naproxen concentrations some 70
times greater than naproxen itself indicating the naproxen–lyso-
zyme conjugate signiﬁcantly improves the renal targeting of
naproxen.
Another well studied kidney-targeted conjugate is with tripto-
lide. Triptolide has been extensively utilized to treat renal diseases
because of its potent anti-inﬂammatory and immunosuppressive
properties but it has both limited water solubility and exerts toxic
effects on the digestive, urogenital, circulatory and reproductive
systems. Zheng and co-workers16,17 synthesized a triptolide–
lysozyme (TPS–LZM) 1:1 conjugate with an ester linkage and
found that the renal concentration of conjugate was 20-fold higher
than from an equivalent dose of drug 30 min after intravenous
(i.v.) injection. The targeting efﬁciency of TPS–LZM was
enhanced from 11.7% to 95.5% and its mean residence time was
moderately prolonged from 3.08 h to 4.10 h. In addition, the TPS–
LZM conjugate showed 22% less hepatotoxicity than triptolide
and produced no adverse effects on the immune system. The
internalization of the TPS–LZM conjugate was mediated by a
600 kDa glycoprotein called megalin, a multi-ligand endocyticreceptor highly expressed in the endocytic pathway of renal
proximal tubules.
The ACE inhibitor captopril has also been conjugated with
lysozyme via a disulﬁde bond and using succinimidyloxycarbonyl-
α-methyl-α-(2-pyridyldithio) toluene (SMPT) as a linker18,19.
Research showed captopril could be released from the conjugate
either enzymatically by β-lyase and/or non-enzymatically by thiol-
disulﬁde exchange with endogenous thiols. The renal concentra-
tion of captopril was increased 6-fold in male Wistar rats and,
compared with the non-targeted drug, the captopril-lysozyme
conjugate reduced proteinuria with no systemic effects on blood
pressure.
According to a recent report, a sunitinib analog named 17864
was linked to lysozyme via a platinum-based linker20. The 17864-
lysozyme conjugate strongly inhibited tyrosine kinase activity and,
after i.v. administration, rapidly accumulated in the kidneys and
gave a 29-fold increase in renal AUC. It also produced sustained
renal drug levels for up to 3 days and showed no anti-ﬁbrotic
effects in normal male C57BI/6 J mice.
A number of other drugs have been linked to lysozyme in
various ways, for example sulfamethoxazole and doxorubicin both
via cis-aconitic anhydride and SB202190 via the platinum (II)-
based Universal Linkage System™ (ULS)21.2.1.2. Low molecular weight chitosan
Another carrier that has been successfully used for kidney-targeted
is acetylated low molecular weight chitosan (LMWC). Chitosan is
a natural copolymer of glucosamine and N-acetyl-glucosamine
derived from chitin. Because of its excellent biocompatibility and
biodegradability, chitosan has been widely used in drug delivery
systems. In investigating a kidney-targeted conjugate with pre-
dnisone, researchers used 50% acetylated LMWC with different
molecular weights22–24 and found that the distribution to the
kidney could be increased 13-fold compared to prednisolone alone
with greatly reduced toxicity. LMWC is speciﬁcally taken up by
renal tubular cells probably via megalin and, compared to
lysozyme, is cleared from the kidneys more rapidly. These
P. Zhou et al.40ﬁndings indicate that LMWCs with molecular weights of 19 and
31 kDa are useful drug carriers with a high degree of safety.2.1.3. Poly(vinylpyrrolidone-co-dimethyl maleic acid)
Yamamoto and co-workers25–27 prepared PVD and investigated how
molecular weight and charge affected its distribution in mouse. Their
results showed that PVD with a molecular weight in the range 6–8 kDa
produced the best renal targeting with about 80% of an administered
dose being distributed to the kidneys. The molecular charge also
affected the distribution where it was found that the more negatively
charged PVD derivatives were eliminated more slowly from the
kidneys. Using a superoxide dismutase conjugate (SOD–PVD), it
was shown that the conjugate exerted a good therapeutic effect in a
mouse model of acute renal failure. However, the mechanism of
absorption of PVD remained unclear and the biocompatibility and
immunogenicity of conjugates requires further study.2.1.4. G3-C12 peptide
A peptide speciﬁc to the galectin-3 carbohydrate recognition
domain (G3-C12) (ANTPCG-PYTHDCPVKR), identiﬁed using
a combinatorial phase display technique, was shown to speciﬁcally
accumulate in mouse kidneys after i.v. injection28–30. This was
done by preparing an FITC-labeled G3-C12 peptide (G3-C12-
FITC) and showing that it selectively accumulated in the kidneys
soon after injection, probably due to reabsorption of the peptide by
proximal renal tubular cells. Taking advantage of this, Geng
et al.31 linked G3-C12 to captopril to produce a kidney-targeted
delivery system for the drug. They showed the conjugate gave a
2.7-fold increase in renal AUC compared with the drug alone and,
in addition, completely released the drug in the kidney as early as
3 min post-injection via disulﬁde bond reduction. These results
indicate the potential of G3-C12 peptide as a novel kidney-targeted
carrier.2.2. Prodrugs
2.2.1. Sugar-modiﬁed prodrugs
In recent years, the signiﬁcance of protein–sugar interactions in
pharmacology and pathology has been increasingly realized. Sugar-
recognition plays a key role in cell–cell, cell–matrix and cell–
molecule interactions including receptor-mediated endocytosis. This
led Suzuki and co-workers to propose glycoconjugates as potential
renal targeting vectors32–34. They used arginine–vasopressin (AVP)
as a model drug and introduced different glycosylated derivatives to
form glycosylated conjugates via an octamethylene group. On the
basis of in vivo and in vitro studies, they concluded that the
alkylglucoside structure (Glc-S-C8-) was necessary for kidney-
targeted, and the targeting efﬁciency depended on the type of sugar
moieties (the length of the alkyl chain, structure of the peptide and
type of linkage) and the size and charge of the molecule. Potential
therapeutic agents were those with a lower molecular weight and
neutral charge.
Lin et al.35,36 successfully synthesized a prednisolone succinate–
glucosamine conjugate (PGC) and a 2-deoxy-2-aminodiglucose–
prednisolone conjugate (DPC) as potential prodrugs of prednisolone.
They conducted cytotoxicity and uptake studies on PGC in HK-2
and MDCK cell lines and, compared with prednisolone, PGC
showed lower cytotoxicity combined with a 2.2-fold greater cellular
uptake. In addition, tissue distribution studies showed that the
concentration of DPC in kidney was 4.9-fold higher than that ofprednisolone. The authors concluded that 2-glucosamine may be a
potential carrier for renal drug targeting.
Liang et al.37 prepared a zidovudine–chitosan oligomer con-
jugate and evaluated the in vitro release of zidovudine in a
pharmacokinetic study in mouse after i.v. administration. The
results indicated the mean residence time of the conjugate was 2.5
times that of zidovudine and that it accumulated in kidney more
than in any other organ.
2.2.2. Amino acid modiﬁed prodrugs
Some endogenous enzymes such as those involved in amino acid L-
decarboxylation and γ-glutamyltranspeptidase have relatively high
concentrations in kidneys. On this basis, some researchers used
substrates of these enzymes to chemically modify drugs in the hope
that drug would be released in proximal tubular cells via action of
the relevant enzyme. Wilk et al.38 synthesized γ-glutamyl-dopamine
(GGDA) and studied its tissue distribution after administration to
mice. They found that the dopamine concentration in kidneys
produced by GGDA was higher than that of an equivalent dose of
dopamine suggesting GGDA was degraded by renal enzymes. The
dopamine targeted to the kidneys signiﬁcantly increased renal blood
ﬂow without any signiﬁcant effect on the heart or on blood pressure.
After oral administration of GGDA, the concentration of free
dopamine in plasma was very low while that in urine was relatively
high39,40. These results indicate that GGDA is a useful way to target
dopamine to the kidney.
Su et al.41 produced an N-acetyl-glutamyl prodrug of predni-
sone and investigated its in vivo distribution and effect on bone
density after administration to rats. The results showed that,
compared with prednisone, the renal concentration of prodrug
was enhanced and the incidence of prednisolone-induced osteo-
porosis was reduced.
2.2.3. Folate modiﬁed prodrugs
The kidney plays an important role in reducing loss of folate. Folate
exists in the body as 5-methylenetetrahydrofolate which is ﬁltered at
the glomerulus and reabsorbed into the renal vascular circulation via
a high-afﬁnity folate binding protein (FBP) concentrated in the
proximal tubular epithelium. In pioneering work by Wang et al.42,
folic acid was attached to diethylene triamine pentaacetic acid
(DTPA) via an ethylenediamine spacer to give a DTPA-folate
conjugate which was rapidly excreted in urine after i.v. administra-
tion to rat. In a subsequent pharmacodynamic study in athymic
tumor-bearing mice, DTPA–folate administered by i.v. injection was
not only taken up by the tumor but also largely distributed to the
kidneys. This observation, together with the rapid clearance of
the DTPA–folate conjugate from FR-negative tissues, illustrates the
crucial role played by folate receptors in the renal uptake of such
conjugates42. To date, the use of folate binding for renal drug
targeting has received limited attention and, since folate receptors
are expressed in organs other than kidney, the physicochemical
properties of the conjugate may be important determinants of the
success of such targeting.3. Other kidney-targeted drug delivery systems
3.1. Nanoparticles
Nanoparticles show great potential as carriers for drug delivery not
least because they can reduce the accumulation of drugs in renal
tubules resulting in decreased renal tubular toxicity. The
Kidney–targeted drug delivery 41physicochemical properties of nanoparticles such as size, surface
charge, shape and density are all important in dictating their ability
to overcome biological barriers and reach their designated cellular
destination.
Manil et al.43 prepared actinomycin D (AD)-loaded isobutyl
acrylate nanoparticles (ADNP) and showed in in vitro and in vivo
experiments that they concentrated in glomerular mesangial cells.
Thus, when 3H–ADNP or 3H–AD were injected into rats with
experimental glomerulonephritis, the uptake ratios (3H–ADNP/3H–
AD) were respectively 6.9-fold (30 min) and 4.0-fold (120 min)
higher than in normal rats. In vitro experiments showed that the
uptake by glomerular mesangial cells was 6-fold higher than by
epithelial cells. Targeting the glomerular mesangium is particularly
valuable for anti-inﬂammatory drugs such as cortisone to treat
glomerular inﬂammation.
Choi et al.44 found that nanoparticles with diameter 75725 nm
could be targeted to the kidney mesangium. By doing so, they
established design criteria for constructing nanoparticle-based ther-
apeutics for targeting diseases that involve the kidney mesangium.
3.2. Liposomes
Liposomes are a well-studied drug delivery system and a component
of several currently marketed products. Singh et al. studied small
unilamellar vesicles (SUVs) loading with methotrexate [(MTX)
SUVs)] linked to Dal K29, an IgG1 monoclonal antibody against
human renal cancer, normal mouse IgG or a nonspeciﬁc mouse
myeloma IgGl45. After incubation with human kidney CaKi-1
cancer cells for 2 h, the Dal K29-linked (MTX)SUVs showed
respectively 6- and 8-fold more binding to CaKi-1 cells than
nonspeciﬁc mouse myeloma IgGl-linked (MTX)SUV or unlinked
(MTX)SUVs. A colony inhibition assay also showed that the Dal
K29-linked (MTX)SUVs were respectively 5 and 40 times better
than Dal K29-MTX and free MTX in inhibiting the growth of the
target CaKi-1 cells. The results suggested that the Dal K29-[(MTX)
SUV] system could be useful in the targeted treatment of renal
cancer.
Tufﬁn et al.46 prepared OX7-coupled immunoliposomes (OX7-
IL) by coupling liposomes with Fab fragments of OX7 mAb
directed against Thy1.1 antigen. The mean diameters of the
liposomes and immunoliposomes were 130 and 170 nm, respec-
tively. Because the glomerular endothelium is fenestrated and no
basement membrane separates glomerular capillaries from the
mesangium, mesangial cells represent a particularly suitable target
for drug delivery by OX7-IL. After i.v. administration to rats,
OX7-IL was found to speciﬁcally target mesangial cells but its
kidney-targeted was blocked when free OX7 F(ab)2 fragments were
co-administered. Rats injected with low-dose doxorubicin encap-
sulated in OX7-IL showed extensive glomerular damage whereas
other parts of the kidney and other organs were spared.4. Conclusions and future perspectives
At present, kidney-targeted drug delivery of drugs is focused on
improving targeting efﬁciency and seeking new carriers. Pharma-
cokinetic and pharmacodynamic studies in pathological conditions
involving severe reductions in glomerular ﬁltration and proteinuria
need to be done to reveal the mechanism of renal uptake of carriers
and prodrugs. A pressing need is to ﬁnd ways to target drugs to the
glomerulus since it plays an important role in the development of
renal disease. With greater understanding of renal structure, furtherdevelopment of molecular pharmacology and more in-depth
research into novel carriers, drug targeting to mesangial cells
and media ﬁbroblasts will greatly improve the clinical treatment of
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